Austedo XR is a prescription medication used to treat tardive dyskinesia and chorea associated with Huntington's disease. It is an extended-release formulation of deutetrabenazine [1].
How does Austedo XR work for tardive dyskinesia?
Austedo XR works by reducing involuntary movements associated with tardive dyskinesia. It affects certain chemicals in the brain, known as neurotransmitters, to help control these movements [1].
What is the difference between Austedo and Austedo XR?
Austedo XR is an extended-release version of deutetrabenazine, meaning it is designed to release the medication slowly over time. Austedo is the immediate-release version [2]. The extended-release formulation may offer convenience by requiring less frequent dosing for some patients [1].
When does Austedo XR patent protection end?
Information on specific patent expiry dates for Austedo XR is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [3]. Patent expiration can be a complex area influenced by patent law and potential legal challenges [3].
What are the potential side effects of Austedo XR?
Common side effects of Austedo XR can include sleepiness, fatigue, dry mouth, and constipation. More serious side effects, though less common, may involve changes in mood, suicidal thoughts, and the risk of parkinsonism. It is important for patients to discuss any side effects with their healthcare provider [1].
How is Austedo XR dosed and administered?
Austedo XR is taken orally once daily. The starting dose and any subsequent adjustments should be determined by a healthcare professional based on the individual patient's response and tolerability [1].
Who manufactures Austedo XR?
Austedo XR is manufactured by Teva Pharmaceuticals [4].